Medical News

RSS

Guided Therapeutics to launch LightTouch non-invasive cancer detection technology at Medica 2009

Guided Therapeutics, Inc. (GT) today announced plans to introduce its LightTouch™ non-invasive cancer detection technology at Medica 2009 in Düsseldorf, Germany November 18 - 20, 2009.

2 Nov 2009

Asking a few questions can help determine risk for lung cancer

A study featured in the November issue of the Journal of Thoracic Oncology confirms the success of a simple questionnaire designed to identify patients at high risk of lung cancer. Initiated in 2001, the current study confirmed 18 cases of cancer of the original 430 patients who qualified as high risk after completing a five-minute questionnaire

2 Nov 2009

InteRNA Technologies and Dana-Farber Cancer Institute team up for cancer research

InteRNA Technologies B.V. and the Dana-Farber Cancer Institute (Boston, USA) have entered into a research agreement to develop microRNA (miRNA)-based therapeutics for cancer.

2 Nov 2009

Medpace signs purchase agreement to acquire Pharma Brains

Medpace, a privately held, global full-service clinical research organization, today announced it has entered into a purchase agreement to acquire Pharma Brains AG, an oncology focused CRO based in Basel, Switzerland.

2 Nov 2009

Vitrolife takes over sales and marketing management of fertility media in UK and Ireland

Vitrolife (STO:VITR) is taking over management of marketing and sales of fertility media in UK and Ireland. “The acquisition is in line with Vitrolife’s strategy to operate using our own personnel and our own management in the most important markets,” says Magnus Nilsson, Vitrolife’s CEO.

2 Nov 2009

HGS and GSK announce results from phase III clinical trials of BENLYSTA

Human Genome Sciences (HGS) and GlaxoSmithKline (GSK) today announced positive results from BLISS-76, the second of two large-scale phase III clinical trials of BENLYSTA(TM) (belimumab) for treating systemic lupus. A full presentation of results from BLISS-52 was recently shared at the 73rd Annual Scientific meeting of the American College of Rheumatology. Both trials succeeded in meeting their primary endpoints, which should make BENLYSTA eligible for approval by the U.S. Food and Drug Administration (FDA).

2 Nov 2009

BENLYSTA meets primary endpoint in BLISS-76 trial for systemic lupus erythematosus

Human Genome Sciences, Inc. and GlaxoSmithKline PLC (GSK) today announced that BENLYSTA™ (belimumab) met the primary endpoint in BLISS-76, the second of two pivotal Phase 3 trials in seropositive patients with systemic lupus erythematosus (SLE). BLISS-76 study results through 52 weeks showed that belimumab 10 mg/kg plus standard of care achieved a statistically significant improvement in patient response rate as measured by the SLE Responder Index at Week 52, compared with placebo plus standard of care.

2 Nov 2009

Dawn simulators can help in alleviating Seasonal Affective Disorder

Scientific Research concludes that waking up to a Lumie Bodyclock can help to beat milder forms of Seasonal Affective Disorder (SAD), otherwise known as the Winter Blues.

2 Nov 2009

American Diabetes Association launches "Stop Diabetes" campaign

Americans earn a failing grade on diabetes awareness, based on survey results released today by the American Diabetes Association. In general, Americans earned a 51% when asked a series of questions about a disease so common that it strikes every 20 seconds. The survey results revealed that many diabetes myths and misconceptions still exist, while the disease's prevalence continues to rise.

2 Nov 2009

Gilead Sciences to present Viread Phase III clinical trial data

Gilead Sciences, Inc. today announced the presentation of three-year (144-week) open label data from two pivotal Phase III clinical trials, Studies 102 and 103, evaluating the safety and efficacy of once-daily Viread® (tenofovir disoproxil fumarate) among adult patients with chronic hepatitis B virus (HBV) infection.

2 Nov 2009

Vertex Pharmaceuticals announces study results of telaprevir-based regimen

More than 80 percent of hepatitis C patients in each arm of the Phase 2 Study C208 achieved a sustained viral response (SVR) with a telaprevir-based regimen according to results of an intent-to-treat (ITT) analysis announced today by Vertex Pharmaceuticals Incorporated.

2 Nov 2009

Polymer Group to acquire Tesalca-Texnovo nonwovens businesses from Grupo Corinpa

Polymer Group, Inc. today announced it has signed a definitive agreement to acquire the Barcelona, Spain-based Tesalca-Texnovo nonwovens businesses from Grupo Corinpa, S.L. in a two-phase process. The purchase is expected to close by the end of November, subject to customary closing conditions.

2 Nov 2009

Optimer Pharmaceuticals presents additional data from Phase 3 fidaxomicin study

Optimer Pharmaceuticals, Inc. today announced the presentation of new data from fidaxomicin's North American phase 3 study at the 47th Annual Meeting of the Infectious Diseases Society of America (IDSA) in Philadelphia, PA.

2 Nov 2009

Global health organizations observe World Pneumonia Day; urge governments to take steps to fight pneumonia

Nearly 100 leading global health organizations from around the world joined forces to recognize the first-annual World Pneumonia Day on November 2 and urge governments to take steps to fight pneumonia, the world’s leading killer of young children.

2 Nov 2009

ExonHit Therapeutics to take part in MAPT study for early detection of Alzheimer’s disease

ExonHit Therapeutics (Paris:ALEHT) together with Toulouse University Hospital and l’Institut de Recherche Pierre Fabre (IRPF) will participate in the Multidomain Alzheimer Preventive Trial (MAPT). The study’s main objective is to assess the efficacy of a multidomain (nutrition, physical exercise, cognitive stimulation) intervention associated with an omega-3 treatment in preventing the decline of cognitive functions in aged and frail individuals.

2 Nov 2009

Intervals between lung cancer diagnosis and treatment may attribute to health care discrepancies

Research published in the November 2009 issue of the Journal of Thoracic Oncology has found that intervals between lung cancer suspicion, diagnosis and treatment may be attributed to health care system discrepancies.

2 Nov 2009

Sosei and ASKA Pharmaceuticals sign distribution agreement

Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565), the biopharmaceutical company, today announced that Sosei Co., Ltd., its wholly owned Japanese subsidiary, has entered into a definitive distribution agreement with ASKA Pharmaceuticals Co., Ltd. ("ASKA", TSE First Section Index: 4514) for the commercialisation of the emergency contraceptive pill SOH-075 (NorLevo(R)).

2 Nov 2009

Saft expands its portfolio with VL 10V Fe Super-Phosphate technology

Saft, the world specialist in the design and manufacture of high-tech batteries for industry, has expanded its range of lithium technologies with the VL 10V Fe Super-Phosphate(TM), the highest power lithium iron phosphate cell on the market. These large cells are designed for defense applications, such as U.S. Navy undersea operations, requiring very high power and safe operation.

2 Nov 2009

Unexpected consequences emerge in patients who are prescribed PPI medications for reflux diseases

Despite being highly effective and beneficial for many patients, unexpected consequences are emerging in patients who are prescribed proton pump inhibitors (PPIs) for reflux diseases. Physicians are warned to monitor these effects and prescribe these medications carefully, according to a new commentary published in the November 2009 issue of Otolaryngology - Head and Neck Surgery.

2 Nov 2009

ACTwatch data indicates low accessibility of artemisinin combination therapy

ACTwatch, a research project led by PSI, in collaboration with the London School of Hygiene and Tropical Medicine, released evidence today that indicates that artemisinin combination therapy, the most effective medicines for treating malaria, continue to have a significantly low presence on the market among populations considered to be most at risk.

2 Nov 2009

Medical News

Guided Therapeutics to launch LightTouch non-invasive cancer detection technology at Medica 2009

Asking a few questions can help determine risk for lung cancer

InteRNA Technologies and Dana-Farber Cancer Institute team up for cancer research

Medpace signs purchase agreement to acquire Pharma Brains

Vitrolife takes over sales and marketing management of fertility media in UK and Ireland

HGS and GSK announce results from phase III clinical trials of BENLYSTA

BENLYSTA meets primary endpoint in BLISS-76 trial for systemic lupus erythematosus

Dawn simulators can help in alleviating Seasonal Affective Disorder

American Diabetes Association launches "Stop Diabetes" campaign

Gilead Sciences to present Viread Phase III clinical trial data

Vertex Pharmaceuticals announces study results of telaprevir-based regimen

Polymer Group to acquire Tesalca-Texnovo nonwovens businesses from Grupo Corinpa

Optimer Pharmaceuticals presents additional data from Phase 3 fidaxomicin study

Global health organizations observe World Pneumonia Day; urge governments to take steps to fight pneumonia

ExonHit Therapeutics to take part in MAPT study for early detection of Alzheimer’s disease

Intervals between lung cancer diagnosis and treatment may attribute to health care discrepancies

Sosei and ASKA Pharmaceuticals sign distribution agreement

Saft expands its portfolio with VL 10V Fe Super-Phosphate technology

Unexpected consequences emerge in patients who are prescribed PPI medications for reflux diseases

ACTwatch data indicates low accessibility of artemisinin combination therapy

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News